IE
VERV

Israel Englander’s Verve Therapeutics VERV Stock Holding History

Israel Englander’s Portfolio VERV Stock Details VERV Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-138,224
Closed -$1.55M – 6495
2025
Q2 		$1.55M Sell
138,224
-1,972,550
-93% -$11.2M ﹤0.01% 4090
2025
Q1 		$9.65M Sell
2,110,774
-1,808,357
-46% -$12.1M 0.01% 2235
2024
Q4 		$22.1M Sell
3,919,131
-1,044,050
-21% -$5.89M 0.01% 1442
2024
Q3 		$24M Buy
4,963,181
+1,092,341
+28% +$6.34M 0.01% 1380
2024
Q2 		$18.9M Buy
3,870,840
+3,256,410
+530% +$20.5M 0.01% 1547
2024
Q1 		$8.16M Buy
+614,430
New +$8.15M ﹤0.01% 2386
2023
Q4 		– Sell
-91,948
Closed -$1.22M – 6582
2023
Q3 		$1.22M Buy
+91,948
New +$1.48M ﹤0.01% 4025
2023
Q2 		– Sell
-28,679
Closed -$414K – 6722
2023
Q1 		$414K Buy
+28,679
New +$562K ﹤0.01% 4715
2022
Q3 		– Sell
-371,671
Closed -$11.9M – 7530
2022
Q2 		$5.68M Buy
+371,671
New +$5.76M ﹤0.01% 2666
2021
Q3 		– Sell
-409,994
Closed -$24.7M – 7285
2021
Q2 		$24.7M Buy
+409,994
New +$17M 0.02% 1029

Other funds holding VERV

GCM
Greenland Capital Management New York $812M AUM 45.54% 1-Year Est. Return
DekaBank Deutsche Girozentrale
DekaBank Deutsche Girozentrale Frankfurt, Germany $59.2B AUM 26.02% 1-Year Est. Return
BIG
Brooklyn Investment Group Brooklyn, New York $3.2B AUM 26.32% 1-Year Est. Return
IA
IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return
Osaic Holdings
Osaic Holdings Scottsdale, Arizona $85.1B AUM 27.35% 1-Year Est. Return

Israel Englander's VERV Position: Q3 2025 in Review

Israel Englander sold out of Verve Therapeutics (VERV) in Q3 2025, closing a stake of 138,224 shares — an estimated $1.55M sold.

Israel Englander first reported a position in VERV in Q2 2021 and held it in 10 quarters. The position peaked at $24.7M in Q2 2021. 6 funds tracked by Wall St. Rank hold VERV as of Q3 2025.

  • Israel Englander reported no remaining Verve Therapeutics position as of Q3 2025 after selling out during the quarter.
  • Israel Englander sold 138,224 Verve Therapeutics shares in Q3 2025, an estimated $1.55M.
  • Israel Englander first reported a position in Verve Therapeutics in Q2 2021 and held it in 10 quarters.
  • Israel Englander's Verve Therapeutics position peaked at $24.7M in Q2 2021.
  • 6 funds tracked by Wall St. Rank held Verve Therapeutics as of Q3 2025.

Based on Millennium Management's 13F filing for Q3 2025, filed 14 Nov 2025.